
Biocon Biologics Ltd., a subsidiary of Bengaluru-headquartered Biocon Ltd., has announced that Kixelle, a biosimilar insulin as part co-developed with NASDAQ-listed Viatris Inc., has received marketing authorisation approval from the European Commission.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3rF8az0
via
IFTTT
0 comments:
Post a Comment